Principal Investigator
Dickran Kazandjian
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20221315
Clinical Trial Summary
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647